Andrews et al.: "Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant"; Primary immunization with two doses of Moderna or Pfizer vaccine provided limited protection against...
by Paul Alexander
symptomatic disease caused by the omicron variant. A Moderna or Pfizer booster after either the Moderna or Pfizer primary course substantially increased protection, but that protection waned over time
Waning meant it went to zero or even below (negative efficacy). See Figure 1 below.
Do these COVID vaccines work? I say no, never did! I am yet to see proof.
This study showed you what we have been arguing and telling you, this being that vaccinal antibody boosting means basically nothing, especially if the waning is fast. The protection via these COVID vaccines have been shown repeatedly, to decline very very rapidly.
Vaccinal antibodies are not a good measure of immunity as it wanes quickly and temporarily lasts. The key issue is that of immune imprinting, priming, prejudicing (original antigenic sin (OAS)) via the initial exposure or vaccine etc. No matter how much the current vaccinal antibodies rise, if they are to the wrong circulating viral spike antigen target, then it is a waste of time and even damaging. In this case, the vaccine is based on the initial Wuhan legacy strain and we now face Omicron sub-variant and thus the recall, the churned out antibodies will be to the Wuhan legacy strain, not Omicron. Thus the immune escape. Yet far worse, is that the vaccinal antibodies do bind, but do not neutralize the virus and actually enhance infectiousness of the virus to the vaccinated person.
I have no confidence that any future planned ‘omicron focused’ bi-valent vaccine will be any better. We will again be vaccinating into a pandemic facing massive infectious pressure with likely sub-optimal immune pressure from vaccinal antibodies given the included spikes would be for the initial legacy Wuhan strain that is long gone and the current BA.4 and BA.5 subvariants would also be likely displaced with new emergent variants. An omicron specific vaccine will end in disaster as all these vaccine makers etc. have done thus far.
“Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time.”
“There was zero (no) impact against the omicron variant from 20 weeks after two ChAdOx1 nCoV-19 doses, “whereas vaccine effectiveness after two BNT162b2 doses was 65.5% (95% confidence interval [CI], 63.9 to 67.0) at 2 to 4 weeks, dropping to 8.8% (95% CI, 7.0 to 10.5) at 25 or more weeks.”
“These findings are consistent with neutralization data for the omicron variant. South African, German, and U.K. studies indicate a reduction in neutralizing activity by a factor of 20 to 40 in serum specimens obtained from recipients of two doses of BNT162b2 as compared with neutralization against early pandemic viruses and by a factor of at least 10 as compared with neutralization against the delta variant.3-5,34 In serum specimens obtained from recipients of two doses of ChAdOx1 nCoV-19, a greater reduction in neutralizing activity was observed, with a high proportion of postvaccination serum samples having neutralizing activity below the limit of quantification in the assay.34 Higher neutralizing activity was observed after a booster dose.3,4,34”